Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast CancerThomas Hatschek, Jonas Bergh, Anne Andersson et al.|JAMA Oncology|2021Cited by 58
Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patientsAntonios Valachis, Thanos Kosmidis, Laura Biganzoli et al.|Future Oncology|2024Cited by 11
Evidence on the occurrence of brain metastases amongst deceased metastatic breast cancer patients from an Uppsala county disease registryHenrik Lindman, Aglaia Schiza, Abdullah Haji et al.|European Journal of Cancer|2018Cited by 0
Abstract P5-02-20: Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trialKang Wang, Theodoros Foukakis, Yajing Zhu et al.|Cancer Research|2023Cited by 0
263TiP Implementing geriatric assessment for dose optimization of CDK 4/6-inhibitors in older breast cancer patients (IMPORTANT trial): A pragmatic randomized-controlled trialAntonios Valachis, T. Kosmidis, Laura Biganzoli et al.|ESMO Open|2024Cited by 0